2023 World Conference on Lung Cancer (Posters)-EP06.06. Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy

EP06.06. Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy - PDF(Abstract)

Back to course

Pdf Summary

Insulin-like Growth Factor 2 mRNA Binding Protein 3 (IGF2BP3) has been identified as a novel regulator of lung adenocarcinoma (LUAD) malignancy. Previous research has shown that IGF2BP3 is highly expressed in various types of tumors, but its functional role in LUAD remains unclear. In this study, the researchers analyzed IGF2BP3 expression data and clinical information from the TCGA LUAD cohort. They found that IGF2BP3 was significantly highly expressed in LUAD tissues compared to normal lung tissues. Furthermore, high expression of IGF2BP3 was associated with shorter overall survival, progression-free survival, and progression-free interval.<br /><br />Using various bioinformatics tools, the researchers explored the functional role of IGF2BP3 in LUAD. They found that IGF2BP3 expression was highly correlated with tumor metastasis, angiogenesis, quiescence, and differentiation. Functional enrichment analysis revealed that IGF2BP3 was significantly associated with several tumor pathways, including estrogen, hypoxia, p53, PI3K, WNT, and MAPK pathways. IGF2BP3 was also associated with various tumor microenvironment signatures and tumor hallmark gene sets. Additionally, metabolic gene set analysis suggested that IGF2BP3 may regulate amino acids, fatty acids, and glucose metabolism.<br /><br />The researchers also investigated the impact of IGF2BP3 on drug sensitivity in LUAD. They found that IGF2BP3 RNA editing was significantly associated with the sensitivity of several drugs commonly used in LUAD treatment. Experimental analysis confirmed that IGF2BP3 positively correlated with the cloning, migration, and invasion ability of LUAD cells.<br /><br />In conclusion, the study shows that high expression of IGF2BP3 in LUAD is associated with poorer prognosis. Bioinformatics and experimental analysis suggest that IGF2BP3 is involved in multiple tumor pathways and affects various aspects of LUAD, including proliferation, metastasis, invasion, tumor microenvironment, and drug sensitivity. This research provides insights into the potential role of IGF2BP3 as a prognostic biomarker and therapeutic target in LUAD.

Asset Subtitle

Xuequan Wang

Meta Tag

Speaker Xuequan Wang

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

Insulin-like Growth Factor 2 mRNA Binding Protein 3

IGF2BP3

lung adenocarcinoma

LUAD

malignancy

tumor

metastasis

angiogenesis

prognosis

therapeutic target